Program Description
Micro- and macrovascular complications affecting the heart and kidneys are a major cause of morbidity and mortality in patients with diabetes and the metabolic syndrome. Aggressive blood pressure (BP) management, in addition to glycemic and lipid management, can provide significant cardiovascular and renal protection in this high-risk patient population. Controlling blood pressure has been shown to reduce cardiovascular disease (CVD) (heart disease and stroke) by approximately 33% to 50%, and microvascular disease (eye, kidney, and nerve disease) by approximately 33%. [National Diabetes Fact Sheet] However, only one third of patients with hypertension (HTN) reach recommended BP goals and many receive no or suboptimal treatment. [Saydah et al, 2004; Schaars et al, 2004; Donnelly et al, 1997; Geiss et al, 2001] This program addresses the challenges faced by clinicians who treat HTN and provides evidence-based strategies for optimizing BP control to prevent cardiovascular and renal complications in patients with diabetes and the metabolic syndrome.

Target Audience
This educational initiative is intended for primary care physicians, cardiologists, endocrinologists, nephrologists, and all health care providers caring for patients with hypertension.

• Apply the seventh report of the Joint National Committee (JNC-7) guidelines, American Diabetes Association (ADA) guidelines, and other evidence-based treatment strategies to optimize HTN management and improve outcomes in individuals with diabetes and the metabolic syndrome
• Understand the role of combination therapy in achieving blood pressure control and preventing cardiovascular and renal complications
• Summarize clinical trials data supporting the use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in high-risk patients

Disclaimer
©2005 Scinexa, LLC. All rights reserved. None of the contents may be reproduced in any form without prior written permission from Scinexa.

The views expressed in this activity are derived from the clinical practice experience of the participating faculty. Therefore, it should not be assumed that the faculty is expressing the views of Scinexa, LLC, the sponsors, accreditors, or any other individual, other than the faculty.  Healthcare providers viewing this site should exercise their professional judgment and consult the full prescribing information, dosages, indications, and warnings, for any drug prior to prescribing. The information presented on this site is intended for healthcare providers located within the United States.  Non-healthcare providers should consult a physician when seeking medical advice. 

Scinexa, LLC operates within the state of New Jersey. By accessing the site both the user and Scinexa, LLC agree that New Jersey laws apply to all matters pertaining to this site, regardless of the user’s location in any state or country.  Users that are in locations where the contents of these site may be deemed as illegal, offensive, or obscene, are fully responsible for complying to their local laws.

Printer settings may vary. Please use landscape layout option.